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ABSTRACT Clostridioides difficile (formerly Clostridium difficile) infection (CDI) can re-
sult from the disruption of the resident gut microbiota. Western diets and popular
weight-loss diets drive large changes in the gut microbiome; however, the literature
is conflicted with regard to the effect of diet on CDI. Using the hypervirulent strain C.
difficile R20291 (RT027) in a mouse model of antibiotic-induced CDI, we assessed disease
outcome and microbial community dynamics in mice fed two high-fat diets in compari-
son with a high-carbohydrate diet and a standard rodent diet. The two high-fat diets ex-
acerbated CDI, with a high-fat/high-protein, Atkins-like diet leading to severe CDI and
100% mortality and a high-fat/low-protein, medium-chain-triglyceride (MCT)-like diet in-
ducing highly variable CDI outcomes. In contrast, mice fed a high-carbohydrate diet
were protected from CDI, despite the high levels of refined carbohydrate and low levels
of fiber in the diet. A total of 28 members of the Lachnospiraceae and Ruminococcaceae
decreased in abundance due to diet and/or antibiotic treatment; these organisms may
compete with C. difficile for amino acids and protect healthy animals from CDI in the ab-
sence of antibiotics. Together, these data suggest that antibiotic treatment might lead to
loss of C. difficile competitors and create a favorable environment for C. difficile prolifera-
tion and virulence with effects that are intensified by high-fat/high-protein diets; in con-
trast, high-carbohydrate diets might be protective regardless of the source of carbohy-
drate or of antibiotic-driven loss of C. difficile competitors.
IMPORTANCE The role of Western and weight-loss diets with extreme macronutrient
composition in the risk and progression of CDI is poorly understood. In a longitudinal
study, we showed that a high-fat/high-protein, Atkins-type diet greatly exacerbated
antibiotic-induced CDI, whereas a high-carbohydrate diet protected, despite the high
monosaccharide and starch content. Our study results, therefore, suggest that popular
high-fat/high-protein weight-loss diets may enhance CDI risk during antibiotic treatment,
possibly due to the synergistic effects of a loss of the microorganisms that normally in-
hibit C. difficile overgrowth and an abundance of amino acids that promote C. difficile
overgrowth. In contrast, a high-carbohydrate diet might be protective, despite reports
on the recent evolution of enhanced carbohydrate metabolism in C. difficile.
KEYWORDS Atkins diet, Clostridium difficile, microbiome
Clostridioides difficile (formerly Clostridium difficile) is an endospore-forming memberof the phylum Firmicutes that is the leading cause of antibiotic-associated and
hospital-acquired diarrhea. C. difficile infections (CDIs) make up 70% of health care-
associated gastrointestinal infections, with symptoms ranging from mild diarrhea in
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mild infections to ulcerative colitis and toxic megacolon in severe infections (1).
Moreover, CDI is financially taxing on U.S. hospital management (2) and is the cause of over
500,000 diagnosed cases and 29,000 deaths annually, according to a 2015 report (3).
Stable and complex microbial communities in the gut act as a natural barrier against
C. difficile (4), but broad-spectrum antibiotics can disrupt the native microflora, allowing
C. difficile to multiply and cause CDI (5). Importantly, C. difficile has innate resistance to
multiple antibiotics and CDI is closely linked to administration of ampicillin, amoxicillin,
cephalosporins, clindamycin, and fluoroquinolones (6). In order to cause successful
infection, C. difficile spores must germinate, grow within the intestinal lumen, and
produce toxins that mediate tissue damage and inflammation (7). Specific chemical
signals are needed for each of these steps. For example, spore germination is promoted
by variety of amino acids and primary bile salts but is inhibited by secondary bile salts
(8); growth can be supported by fermentation of amino acids or carbohydrates but is
inhibited by short-chain fatty acid (SCFA) products of carbohydrate fermentation
(9–11); finally, toxin production is inhibited by several amino acids, particularly cysteine
(12). Thus, it is logical that diet might affect the incidence and severity of CDI, and yet
the literature is contradictory on relationships between diet and CDI.
Several studies have suggested that high-carbohydrate/low-protein diets can miti-
gate antibiotic-induced CDI. Moore et al. (13) hypothesized that poor nutrient status
would worsen CDI but instead found that protein-deficient diets (with increased
carbohydrate content) mitigated CDI severity in C57BL/6 mice infected with hyperviru-
lent strain VPI 10463 (ribotype 078 [RT078]). Another study using humanized mice
inoculated from antibiotic-induced dysbiotic subjects reported increased lumen amino
acid concentrations and severe CDI compared with those inoculated from control
subjects (11). The same study showed that C. difficile strain 630 expressed the proline
reductase, PrdA, only in dysbiotic mice and that prdB mutants unable to use proline as
the Stickland electron acceptor failed to colonize mice. Finally, they showed that
low-protein and, specifically, low-proline diets lessened colonization and virulence. A
separate study found that mixtures of microbiota-accessible carbohydrates (MACs), or,
specifically, inulin, decreased C. difficile burdens in humanized mice, while stimulating
growth of carbohydrate-utilizing microbes and SCFA production (10).
In contrast, other studies have implicated carbohydrates, specifically, simple sugars,
in the proliferation of hypervirulent, epidemic C. difficile strains. One study reported on
the independent evolution of mechanisms to utilize the artificial sweetener trehalose in
RT027 and RT078 and showed that trehalose supported growth of these ribotypes in
vitro (14). Trehalose also increased toxin production and decreased survival in a
humanized mouse model of CDI but did not increase C. difficile burden. Similarly, Kumar
and colleagues (15) reported positive evolutionary selection in the fructose phospho-
transferase system and for several other enzymes involved in the transport and
fermentation of simple sugars in recently evolved strains of C. difficile, including RT027.
That study also reported that glucose and fructose enhanced growth and sporulation
of RT027 in vitro and shedding in a mouse model of CDI, but relationships between
dietary monosaccharides and virulence were not reported.
Western diets would seem to favor CDI since they are enriched in both proteins and
simple sugars and yet are deficient in MACs and other fiber sources (16), and rates of
CDIs are indeed highest in developed countries (17). Modern weight-loss diets such as
Atkins and ketogenic diets are extreme because the majority of calories are from fat and
protein and because carbohydrates typically contribute less than 10% of caloric intake
(18, 19). These diets have been wildly popular; for example, Dr. Atkins’ “Diet Revolution”
is the best-selling diet book in history (20). Keto diets are similar to Atkins’ diets but
tend to be more extreme, reducing both dietary carbohydrate and protein levels. And
yet, despite the increasing evidence tying C. difficile evolution and pathogenesis to diet
and the continuing revolution of modern diets with extreme macronutrient composi-
tion, diet has not been featured as a major factor in models of CDI (17).
Here, we assessed the effect of diet, including a high-fat/high-protein Atkins-like
diet, a high-fat/low-protein keto-like diet resembling the medium-chain-triglyceride
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(MCT) diet, and a high-carbohydrate diet, on the outcome of antibiotic-associated CDI
using hypervirulent C. difficile strain R20291 and described concomitant changes in
microbial community diversity and composition.
RESULTS
A high-fat/high-protein diet exacerbates CDI, and yet a high-carbohydrate diet
provides protection. To determine whether diet affects the progression of CDI, groups
of five mice were fed diets differing in macronutrient composition (Fig. 1) as follows: a
high-fat/high-protein diet, a high-fat/low-protein diet, a high-carbohydrate diet, and a
standard laboratory diet (see Table S1 to S4 in the supplemental material). To quantify
the effect of the diets on CDI severity, morbidity and mortality were examined over the
course of the experiment (Fig. 2) using established metrics (21) with amendments as
described in Materials and Methods. All infected mice fed the standard laboratory diet
developed mild CDI signs but eventually recovered. The mean time of CDI sign onset
was 2.8  0.4 days, and the mean recovery time was 4.8  0.4 days. In contrast, only
two of the mice fed the high-carbohydrate diet exhibited mild symptoms, and they
quickly recovered. The mean time of CDI sign onset was 2.0  1.8 days, and the mean
FIG 1 Experimental timeline and macronutrient contents of the diets. (a) High-carbohydrate (blue), high-fat/low-
protein (green), or high-fat/high-protein (red) diets were introduced on day 3. An antibiotic cocktail (solid outline)
and clindamycin (black-filled circles) were given on day 13 and day 16, respectively. Mice were challenged with C.
difficile R2027 spores on day 17 (dashed outline). Circles with numbers indicate the days on which fecal samples
were collected. Stool collection took place prior to manipulation of mice or experimental treatment. (b) A ternary
plot depicting micronutrient contents (% Fat, % Protein, % Carbohydrate) of high-carbohydrate (blue), high-fat/
low-protein (green), high-fat/high-protein (red), and standard laboratory (purple) diets.
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recovery time was 3.0  1.3 days. The rest of the animals in this group never developed
any CDI signs. Mice fed the high-fat/low-protein diet showed CDI symptom onset
heterogeneity. Two animals developed severe CDI and became moribund. Meanwhile,
three animals developed mild to moderate CDI signs similar to those seen with the
FIG 2 Effect of diet on mouse survival and CDI severity postinfection. (a) Mean disease severity scores (black
dots with connected black trendline) for each diet following CDI challenge; 25th and 75th percentiles are
shown. Colored dots represent severity scores for individual mice. Dashed lines represent a score of 6, the
clinical endpoint. Groups marked A, B, or C indicate statistically significant differences (P  0.05, two-way
repeated-measures [ANOVA]) in disease severity between mice fed a high-carbohydrate diet versus a
high-fat/high-protein diet (letter A), a standard laboratory diet versus a high-fat/high-protein diet (letter B), or
a high-carbohydrate diet versus high-fat/low-protein diet (letter C). There were significant (P  0.001, two-way
repeated-measures ANOVA, **) changes in CDI severity through time in infected mice fed a standard
laboratory diet and a high-fat/high-protein diet. (b) Kaplan-Meier survival curves for mice fed a high-
carbohydrate diet (blue, n  5), high-fat/low-protein diet (green, n  5), high-fat/high-protein diet (red, n  5),
and standard laboratory diet (purple, n  5), all following CDI challenge. The high-fat/high-protein diet
significantly (P  0.003, log rank test, *) reduced survival of infected mice. All uninfected mice fed the standard
laboratory diet showed no CDI signs (score of 0) for the duration of the experiment (not shown).
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standard diet and recovered within a week postinfection. The mean time of CDI sign
onset was 3.2  0.4 days, and the mean recovery time was 6.0  0.0 days. Strikingly, all
mice fed the high-fat/high-protein diet developed severe CDI signs and were eutha-
nized within 4 days following C. difficile challenge. For these mice, the mean time of CDI
sign onset was 1.6  0.5 days. The difference in survival rates between the mice fed the
high-fat/high-protein diet and all other animal groups was significant (P  0.003 [log
rank test]). Surviving animals in all groups resolved all CDI signs (score of 0) within 8
days and remained healthy for the remainder of the experiment. A control cohort of
uninfected mice fed the standard laboratory diet remained healthy and showed no CDI
signs for the duration of the experiment (not shown).
Reduced microbial diversity is associated with changes in diet, antibiotic
treatment, and CDI. To understand changes in gut microbial diversity due to exper-
imental manipulations, alpha diversity was analyzed, as measured by richness (ob-
served sequence variants [SVs]) (Fig. 3a), Simpson’s evenness (see Fig. S1 in the
supplemental material), and Shannon diversity (Fig. 3b) over the course of the exper-
imental timeline. All animal groups showed significant (P  0.05 [analysis of variance
{ANOVA}]) change in diversity over time, due to decreases in richness and evenness
corresponding to changes in diet (day 13) or antibiotic treatment (day 17) and/or
disease status (days 18 and 19).
Specifically, there were significant differences (P  0.05 [ANOVA]) in richness, even-
ness, and Shannon diversity between the diet groups after mice were fed the experi-
mental diets for 10 days (day 13), exemplified by significant decreases in richness and
Shannon diversity after administration of the high-carbohydrate diet (day 0 versus day
13) (P  0.05 [ANOVA and Tukey’s honestly significant difference {HSD} test]) and
richness after administration of the high-fat/high-protein diet (day 0 versus day 13)
(P  0.05 [ANOVA and Tukey’s HSD test]). Diversity results were also distinct in the diet
groups following antibiotic treatment; in particular, there was a significant loss of
diversity after antibiotic treatments (day 13 versus day 17) (P  0.05 [ANOVA and
Tukey’s HSD test]) in mice fed the standard laboratory diet (evenness and Shannon
diversity) and the high-carbohydrate diet (Shannon diversity). The diet groups were
also distinct with regard to all three diversity indices following inoculation with spores
(day 18 and day 19), and there were significant losses in diversity in mice fed the
standard laboratory diet and the high-fat/high-protein diet corresponding to CDI
development (day 17 versus day 18) (P  0.05 [ANOVA and Tukey’s HSD test]).
For mice fed the standard and high-fat/low-protein diets, most alpha diversity
metrics returned to their diet-acclimated states within 30 days post-C. difficile challenge
(day 13 versus day 47) (P  0.05). In contrast, gut microbiome richness did not return
to normal in mice fed the high-carbohydrate diet over this time course (day 10 versus
day 47) (P  0.05).
Microbial communities transitioned through a common pattern in response to
experimental manipulations. To assess microbial community changes over the ex-
perimental timeline, Bray-Curtis dissimilarity was calculated and visualized by nonmet-
ric multidimensional scaling (NMDS). This analysis revealed a common pattern of
microbial community transition through the experimental time course in all groups for
the following parameters: diet-associated state, antibiotic-associated state (Abx), CDI-
associated state (CDI), and recovery state (recovery) (Fig. 4). Although overall patterns
in the progression of these states were similar, some diet-specific effects were apparent.
Infected mice fed the standard laboratory diet progressed through distinct phases
of transition and returned to a quasi-pre-CDI community structure, as indicated by
overlapping the “Standard” and “Recovery” confidence ellipses (Fig. 4a). However, some
microbial groups did not return after the experimental treatments, exemplified by the
phylum Tenericutes (Fig. S2 to S5). In contrast, the diet-associated and recovery ellipses
did not overlap in mice fed the high-carbohydrate and high-fat/low-protein diets
(Fig. 4b and c), indicating incomplete restoration of the gut microbial communities. The
analysis also highlighted the large variability in microbial community structure in mice
fed the high-fat/low-protein diet following antibiotic treatment (Fig. 4c), which was
High-Fat/High-Protein Diet Exacerbates C. difficile
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FIG 3 Effect of diet and treatment on alpha diversity. (a) Observed sequence variants (SV) and (b) Shannon diversity were
calculated for uninfected mice fed a standard laboratory diet (orange, n  5) and for infected mice fed a standard
laboratory diet (purple, n  5), high-carbohydrate diet (blue, n  5), high-fat/low-protein diet (green, n  5), or high-fat/
high-protein diet (red, n  5). Gray boxes highlight comparisons between groups after a change in diet on day 13 and
antibiotic treatments on day 17, postinfection on days 18 and 19, and recovery on days 30 and 47. Administration of
experimental diets (solid tan line, x axis) and time points after antibiotics administration (solid black line, x axis) and C.
difficile challenge (dashed black line, x axis) are indicated. Black dots above and below box plots represent outliers.
Asterisks (*) indicate significant (P  0.05) loss of diversity in within-group pairwise comparisons. Filled diamonds (})
indicate significant (P  0.05 [ANOVA]) differences between groups on a given day.
Mefferd et al.
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FIG 4 NMDS analysis based on Bray-Curtis dissimilarity. Each panel presents a visualization of the same data and highlights the analysis for infected
mice fed a (a) standard laboratory diet, (b) high-carbohydrate diet (blue), (c) high-fat/low-protein diet (HF/LP, green), and (d) high-fat/high-protein diet
(HF/HP, red). Colors are shaded to show time progression through the experiment. Data representing uninfected mice fed a standard laboratory diet
(dark gray triangles) are featured in all panels. Ellipses represent standard errors of the mean (95% confidence) for samples associated with the
standard laboratory diet (labeled “Standard,” days 0 and 3), diet-associated microbiomes (days 10 and 13), antibiotic treatments (labeled “Abx,” day
17), CDI (days 18 to 22), and recovery (days 30 and 47) for the colored data points associated with each experimental group. A 95% confidence ellipse
of samples representing mice fed a high-fat/low-protein diet (panel c) on day 17 was not included, as it was large and included nearly all points in
the data set. This indicates that there was variability in the high-fat/low-protein samples after antibiotic treatments, and results must be interpreted
with caution due to small sample size. For guidance, an amended experimental timeline image from Fig. 1 is included.
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generally consistent with the heterogeneous CDI outcomes of the mice on that diet. A
recovery phase was not observable in mice fed the high-fat/high-protein diet due to
100% mortality of these mice by day 21 (Fig. 4d). Uninfected mice fed the standard
laboratory diet clustered together throughout the experiment.
Diet impacted antibiotic- and recovery-associated microbial communities. To
better investigate the effect of diet on microbial community response to specific
treatments, Bray-Curtis dissimilarity was calculated for crucial time points in the exper-
iment (Fig. 5). Diet-specific microbial communities developed prior to antibiotic treat-
ment (day 13), as indicated by nonoverlapping ellipses and highly significant analysis
of similarity (ANOSIM) values (P  0.05; R  0.912) for standard, high-carbohydrate, and
high-fat/high-protein diets on day 13; however, the community structures of high-fat/
low-protein-fed animals were not distinct (Fig. 5a).
The distinctness of the microbial communities was disrupted by antibiotic treatment
and CDI, as evidenced by overlapping ellipses and insignificant ANOSIM values for day
17, day 18, and day 19, indicating the dominant role of the antibiotic treatments and
CDI over the diet treatments in structuring the microbial community (Fig. 5b to d).
Following recovery, diet-specific clustering patterns reemerged in the recovery phase
on day 30 and day 47 (Fig. 5e and f).
Similar to CDI severity signs, the high-fat/low-protein microbiomes were heteroge-
neous during these treatments. However, no connection was observed between indi-
vidual animal changes in microbial communities and disease severity or onset.
Diet and antibiotics administration profoundly altered the microbiome com-
position. Similarity percent (SIMPER) analysis (22) identified 51 SVs that contributed to
50% of microbial community dissimilarity between all pairwise comparisons of the
diet-specific microbiomes throughout the experiment (Fig. 6). More than half of these
SVs belonged to the Clostridiales, predominantly the families Lachnospiraceae (19/51)
and Ruminococcaceae (9/51), and were dominated by uncultivated genera. Most Lach-
nospiraceae SVs decreased in abundance after administration of the experimental diets,
particularly the high-fat/low-protein diet and the high-carbohydrate diet, and were
further reduced following antibiotic treatment and CDI. The Ruminococcaceae SVs were
more variable in response to the diets but were also strongly depleted following
antibiotic treatment.
Several other groups also showed strong patterns. We compared the relative
abundances of these taxa at key time points using ANOVA and Tukey’s HSD test and
found significant differences in their abundances with respect to uninfected mice
across the experimental timeline. Two Muribaculaceae SVs became depleted in abun-
dance in the high-carbohydrate and high-fat/low-protein groups but then bloomed
(day 17) (P  0.05) and crashed following antibiotic treatment and infection (days 18
and 19) (P  0.05) and never recovered (days 30 and 47) (P  0.05). Also, two Alistipes
SVs slightly increased in abundance after administration of the experimental diets (day
17) (P  0.05), followed by a reduction after antibiotic treatment and/or CDI. An SV
affiliated with the Clostridium innocuum group emerged at different times after the
antibiotic treatment in all the antibiotic-treated mice. Further, abundances of some
members of the Proteobacteria, including Escherichia/Shigella and an uncultivated
member of the Enterobacteriaceae, expanded after the antibiotic treatment, and yet
abundances of Parasutterella decreased in all antibiotic-treated mice (days 17 and 18)
(P  0.05). Also, an SV in the order Parabacteroides expanded after the antibiotic
treatment (day 19) (P  0.05) in all but the high-fat/low-protein diet treatments. The
relative abundance of Akkermansia increased after C. difficile challenge (day 18 and 21)
(P  0.05) irrespective of diet.
DISCUSSION
The mammalian gut microbiota is crucial for host health and provides colonization
resistance against various enteric pathogens (23). Exposure to broad-spectrum antibi-
otics leads to the depletion of commensal microbiota, an effect which can be exploited
by pathogens such as C. difficile (24). Diet is an important force that determines gut
Mefferd et al.
January/February 2020 Volume 5 Issue 1 e00765-19 msystems.asm.org 8
 on F
ebruary 25, 2020 at U
N
LV
 Libraries
http://m
system
s.asm
.org/
D
ow
nloaded from
 
FIG 5 NMDS analysis based on Bray-Curtis dissimilarity for days 13, 17, 18, 19, 30, and 47. Each panel presents an
ordination of samples from uninfected mice fed a standard laboratory diet (orange) and from infected mice fed a
standard laboratory diet (purple), high-carbohydrate diet (blue), high-fat/low-protein diet (green), or high-fat/high-
protein diet (red) for days (a) 13, (b) 17, (c) 18, (d) 19, (e) 30, and (f) 47. Ellipses represent standard errors of the mean
(95% confidence). Data representing 95% confidence are not shown for the mice fed a standard laboratory diet and
high-fat/low-protein diet on days 17, 18, and 19, as the associated data fields were large and included nearly all
points in the data set. Also, 95% confidence ellipses are not shown for mouse groups with significant mortality, as
the calculation cannot compute with n  4.
High-Fat/High-Protein Diet Exacerbates C. difficile
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microbial composition and function (25). Consequently, several studies have demon-
strated the effects of dietary components on C. difficile growth, physiology, and
pathogenesis both in vitro and in antibiotic-induced animal models of CDI; however,
those studies have been contradictory regarding the relative importance of proteins
and carbohydrates in effects on CDI. The goal of this study was to broadly assess CDI
outcomes and microbial community responses to diets with extreme differences in
macronutrient composition following antibiotic treatment.
Effect of high-carbohydrate diets on antibiotic-induced CDI. Improved gut
health due to high-carbohydrate diets, especially those rich in fiber, has been well
documented and is suggested to be related to the production of SCFAs by gut
microbes (26–30). Some studies have pointed to the importance of MACs (specifically,
inulin) in mitigation of CDI (10); however, the inulin content of the high-carbohydrate
diet in our study was low (2.1% [wt/vol]). Instead, the major sources of carbohydrates
were corn starch (43.5% [wt/vol]), maltodextrin (14.4% [wt/vol]), and sucrose (11.0%
[wt/vol]). The highly digestible corn starch and maltodextrin incorporated in these diets
would be depolymerized to monosaccharides readily. Thus, our study results suggest
FIG 6 SIMPER analysis results displaying top SVs responsible for dissimilarity between experimental groups. The heat map indicates the mean relative
abundances of 51 SVs that contributed cumulatively to 50% of community dissimilarities at each time point among the mice fed the standard laboratory diet,
high-carbohydrate diet (High-Carb), high-fat/low-protein diet (HF/LP), and high-fat/high-protein diet (HF/HP). Each square represents the mean relative
abundance of the given SV on a particular day for a particular diet. Higher intensity of brown coloring correlates with higher relative abundance.
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that a high-carbohydrate diet that is correspondingly low in protein can be protective
against CDI, irrespective of the specific carbohydrate composition.
This result superficially contradicts reports of recent adaptations enhancing the
transport, metabolism, and general physiology of different strains of C. difficile in
response to glucose, fructose, and trehalose (14, 15). However, the study on glucose
and fructose metabolism did not describe any effects of sugars on the pathogenesis of
RT027. Instead, they reported that monosaccharides promoted growth and sporulation
in vitro and colonization in a mouse model of CDI. Thus, it appears that monosaccha-
rides or easily digestible polysaccharides might promote C. difficile colonization while
simultaneously limiting CDI overgrowth and pathogenesis. Indeed, we found that mice
fed the high-carbohydrate diet became long-term carriers of low-abundance popula-
tions of C. difficile, whereas mice fed the standard and high-fat/low-protein diets
cleared C. difficile within 30 days post-C. difficile challenge (see Fig. S6 in the supple-
mental material). These studies paint a somewhat complicated picture with regard to
the effects of dietary sugars on C. difficile and suggest that those effects should be
addressed using carefully controlled and documented experiments that take into
account the strain of C. difficile and the precise diet used in the animal model. In this
regard, it is noteworthy that recent studies on the effects of sugars on C. difficile have
not reported the diet used for the experiments (14, 15). In summary, the available data
suggest the following: (i) any dietary sugar protects from antibiotic-associated CDI; (ii)
monosaccharides and easily digestible polysaccharides might promote low-level C.
difficile colonization that might be important for C. difficile epidemiology; and (iii) MACs
might simultaneously protect against CDI and select against C. difficile colonization.
Effect of a high-fat/high-protein, Atkins-like diet on antibiotic-induced CDI. Our
experiments revealed that CDI was exacerbated in mice fed high-fat diets, particularly
in mice fed a high-fat/high-protein, Atkins-like diet. A high-fat diet was also observed
to intensify CDI in a hamster model of infection (31); however, to our knowledge, a
high-fat/high-protein diet has never been explored in animal models of CDI, as typical
diets used for mouse and hamster models of CDI have 10% kcal from fat and 30%
kcal from protein. The poor CDI outcome observed here for mice fed the high-fat/high-
protein diet compared with the high-fat/low-protein diet is consistent with known
relationships between dietary protein and CDI in both laboratory mice with native
murine microbiota (13) and humanized mice fed a defined amino acid diet deficient in
the Stickland electron acceptor proline (11). The major diets used in these other studies
used relatively low (20%) concentrations of protein provided as casein. The protein
source in our high-fat/low-protein diet was also casein (22.8% [wt/vol]) (Table S2), yet
that in the high-fat/high-protein diet was whey protein (50.0% [wt/vol]) (Table S1) (32).
However, since casein and whey protein are both derived from milk and have similar
amino acid contents (Table S1 and S3) and since they are provided as prehydrolyzed
peptides, we expect that they would differ little in amino acid availability. Nevertheless,
because the protein sources were not identical, further work is needed to disentangle
any effects of protein source, digestibility, or abundance on CDI.
Effects of protein on CDI could be direct and/or indirect. C. difficile can use many
different amino acids as Stickland donors, and both proline and glycine can be used as
Stickland acceptors (9). And yet the C. difficile proline reductase (PrdA) was expressed
only in humanized mice inoculated with dysbiotic microbiomes (11), suggesting that C.
difficile may not compete well for proteins or amino acids with healthy microflora. In
“healthy” humanized mice, PrdA was expressed by three members of the Lachno-
spiraceae, suggesting they might be important competitors for proline and other amino
acids. Lachnospiraceae was also one of only three bacterial families that were signifi-
cantly depleted in the dysbiotic humanized mice, along with Ruminococcaceae and
Bacteroidaceae. In our study, most of the bacteria that contributed to microbiome
variation belonged to Lachnospiraceae or Ruminococcaceae, and all of these organisms
decreased in abundance in response to the diets and/or antibiotic treatment, suggest-
ing they may be important competitors of C. difficile for amino acids in the lumen (33).
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Those two families are also dominant producers of butyrate in the gut (30), which
directly inhibits C. difficile growth in vitro (10). In addition, butyrate also provides
protection against CDI by improving intestinal barrier function and reducing intestinal
inflammation through overexpression of hypoxia-inducible factor 1 (HIF-1) (34). Lach-
nospiraceae in particular is a dominant bacterial family in the gut microbial communi-
ties of many mammals, and many members of the family provide benefits to the host
(35). A member of this family has also been documented to provide colonization
resistance to C. difficile in a CDI mouse model (36) and has been shown to produce iso
(3-hydroxy) bile acids (37), which are inhibitors of C. difficile growth. Thus, it appears
that members of Lachnospiraceae and Ruminococcaceae act against C. difficile through
independent mechanisms, including competition for resources and production of
inhibitory SCFAs and secondary bile acids. In our study, the high-fat/high-protein diet
would lead to an abundance of oligopeptides and free amino acids in the lumen and
could provide a selective advantage that leads to C. difficile overgrowth when coupled
with the loss of Lachnospiraceae and Ruminococcaceae. Diet-induced or antibiotic-
induced loss of Lachnospiraceae and Ruminococcaceae might not be a significant
problem in mice fed other diets, particularly the high-carbohydrate diet, because of the
low concentrations of peptides and amino acids and/or the healthful effects of SCFAs
resulting from carbohydrate fermentation by other microorganisms (see above).
High-protein diets have more-general consequences for gut health that may exac-
erbate pathogenesis. Proteins that are not easily digested cause a surplus of dietary
protein reaching the distal gut that can be acted upon by protein-fermenting bacteria.
Fermentation of sulfur-containing amino acids can lead to excessive hydrogen sulfide,
via desulfurlyation of cysteine and methionine, which inhibits host cytochrome c
oxidase, damages colonic cell genomic DNA, alters cellular pathways, inhibits host-cell
butyrate oxidation, and reduces the life span of colonocytes (38, 39). Production of
ammonia due to protein fermentation (ammonification) can result in reduced gut
health through decreased SCFA production, increased paracellular permeability of gut
epithelial cells, and altered epithelial cell morphology (40, 41). And yet, the effect of the
high-fat/high-protein diet alone on the health of mice does not explain the health
problems in those mice, as the experimental diets were given for 10 days prior
administration of antibiotics and C. difficile challenge and there were no observable
changes in behavior or host health.
Effect of a high-fat/low-protein keto-like diet on antibiotic-induced CDI. Mice
fed the high-fat/low-protein diet showed variability in disease severity and survival
(Fig. 2) and highly variable microbiome compositions after antibiotic treatments (Fig. 4).
Thus, the effect of fats on CDI is uncertain. The high-fat/low-protein diet was high in
saturated fats, as the fat source was hydrogenated coconut oil (33.3% [wt/vol]) (Ta-
ble S2). Coconut oil is 90% saturated fatty acids and consists of medium-length chains
rich in lauric acid (C8:0) (42). This diet closely mimics the MCT diet, which is a version
of ketogenic diet (19). Diets high in saturated fats can increase the incidence of colitis
in immunocompromised mice due to increased inflammatory response (43). Such an
effect points to plausible hypotheses with respect to the mechanisms by which healthy
mice fed the high-fat/low-protein diet may have experienced increased CDI severity
and reduced survival following C. difficile challenge. However, the high-fat diets used in
these studies also had low carbohydrate content, which itself may have been an
important factor in disease progression in some animals.
Effect of diet on C. difficile pathogenesis. In addition to the direct effects of diet
on C. difficile germination, growth, and sporulation and the indirect effects mediated by
ecological interactions, diet may also affect C. difficile by directly altering the expression
of pathogenesis factors. Interestingly, in vitro studies on C. difficile strain VPI 10463
showed that a blend of nine amino acids, including proline and cysteine, downregu-
lated toxin production (44, 45). This result superficially contradicts our results and those
reported by others (11) showing that dietary proteins exacerbate CDI in mice, under-
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scoring the complexity of CDI and the need for additional studies to better understand
the ecological and molecular mechanisms governing diet-specific CDI outcomes.
Other microbial community responses to diets, antibiotics, and CDI. Following
changes in diet, mice developed distinct microbial communities, which were then
disturbed by antibiotic treatments and CDI (Fig. 4; see also Fig. S2 to S5). The shift in
community composition after diet and antibiotics administration was accompanied by
reduced alpha diversity associated with the effects of diet, antibiotic treatment, and CDI
(Fig. 3; see also Fig. S1), which is consistent with previous work. Perturbations to gut
microbial communities resulting from administration of antibiotics can result in CDI due
to loss of colonization resistance, especially following a course of antibiotics, as seen in
humans (46) and across CDI mouse and hamster animal models (5, 47, 48). Typically,
reduced colonization resistance and increased susceptibility to CDI are marked by a
decrease in gut microbial diversity (5, 49), and yet a recent report suggested that CDI
susceptibility and severity are independent of alpha diversity (10). Likewise, our work
showed loss of diversity in infected mice across all experimental diets (Fig. 3) and yet
also showed significantly different survival and severity outcomes between the groups
(Fig. 2). This demonstrates that diet plays a critical and dominant role in CDI disease
patterns over microbial diversity per se.
In addition to the changes in Lachnospiraceae and Ruminococcaceae abundances
described above, the abundances of several other microorganisms changed through-
out the experiment. There was a loss of a member of the genus Parasutterella after a
change in diet (Fig. 6). Parasutterella species are a part of the core gut microbiome in
humans and mice, with occasional associations with disease. A study characterizing
Parasutterella isolated from mouse guts showed that the presence of this organism
significantly changed patterns of aromatic amino acid metabolism in the gut and that
the organism is crucial for bile acid metabolism and homeostasis (50). This is especially
important since conjugated primary bile salts are required for spore germination
whereas secondary bile acids are known inhibitors of sporulation and growth of C.
difficile. Therefore, Parasutterella could play an important role in colonization resistance
through the modulation of the composition of the bile acids pool (51).
Muribaculaceae (formerly family S24-7) abundance decreased after administration of
the high-carbohydrate and high-fat/low-protein diets (Fig. 6). Members of Muribacu-
laceae are well adapted to the mouse gut microbiome (52) and may comprise up to 685
species-level clusters (53). Further, analysis of the 157 draft genomes of the members
of Muribaculaceae showed them to be highly enriched in glycoside hydrolases, sug-
gesting an ability to deconstruct complex carbohydrates such as MACs and thereby
promote SCFA production (53, 54).
The increase in Alistipes abundance after the diet changes and the reduction in
abundance after antibiotic treatment might be indicative of general antibiotic suscep-
tibility of this organism. Members of Alistipes are suggested to be protective against CDI
(48), and depletion of these microbes has been associated with CDI (55). Another study
on fecal microbiota transplant (FMT) treatments for CDI documented an increased
abundance of Alistipes after the FMT (56). Hence, the protective effect provided by
members of the genus Alistipes needs to be evaluated carefully.
The increased abundance of Clostridium innocuum after antibiotic treatment in all
diet groups can be attributed to its ability to produce peptidoglycan precursors with a
C-terminal serine, which have a low affinity for vancomycin (57). This organism’s
resistance to vancomycin is a potential cause of antibiotic-associated diarrhea in
humans, with effects similar to those seen with CDI (58).
Increased Akkermansia abundance post-C. difficile infection could be linked with
increased mucus levels. In human CDI, patients with active CDI tend to secrete acidic
mucins composed of MUC1 with altered oligosaccharide composition (59). We specu-
late that the increased abundance of Akkermansia postinfection (Fig. 6) could represent
a result of this mucus secretion (60).
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The transient surge in Proteobacteria abundance after antibiotic treatment in all
mouse groups is a known response to loss of the dominant gut taxa (61). Proteobacteria
induce inflammation (61) and provide an environment conducive for invasion by
pathogens such as C. difficile (62). However, this increase in the abundance of members
of Proteobacteria was also seen in mice fed the high-carbohydrate diet, indicating that
blooms of Proteobacteria are insufficient to induce CDI. Parabacteroides abundance also
increased in patients with recurrent CDIs (63). Parabacteroides produces succinate (64),
which has been found to promote C. difficile growth following antibiotic treatments
(65). Thus, the survival of Parabacteroides after antibiotic treatments could favor the
proliferation of C. difficile in infected mice.
Conclusion. This study revealed large differences in the outcomes of CDI in an
antibiotic-induced mouse model using hypervirulent strain R20291 (RT027) and that
the differences were due to diets representing extremes of macronutrient composition.
The poor outcome seen with mice fed an Atkins-like diet demands a close look at
whether Atkins, ketogenic, or other high-fat/high-protein diets create high risk for CDI
in humans, particularly if members of the Lachnospiraceae and Ruminococcaceae are
disrupted by antibiotics. In contrast, the protective effect of a high-carbohydrate diet,
despite high monosaccharide and digestible starch content, is inconsistent with recent
reports on the possible importance of the effects of simple sugars on CDI. Since
monosaccharides and digestible starch would not be expected to improve gut health,
the apparent protective effect may be due to the low protein and/or fat content rather
than to protective effects of carbohydrates per se.
MATERIALS AND METHODS
Bacterial growth conditions and spore harvest. C. difficile R20291 (RT027), a gift from Nigel Minton,
University of Nottingham, was grown on Bacto brain heart infusion (BHI) agar plates in an anaerobic
chamber (10% CO2, 10% H2, 80% N2) at 37°C for 7 days. Bacterial cells and spores were collected from
plates with confluent growth by flooding the plates with ice-cold, autoclaved deionized (DI) water.
Spores were pelleted by centrifugation and resuspended in fresh deionized water for three wash steps.
The spores were harvested by density gradient centrifugation via the use of a 20% to 50% HistoDenz
gradient. The spore pellet was washed five times with autoclaved deionized water and stored at 4°C.
Schaeffer-Fulton-staining was performed to determine the purity of spore harvest.
Animals. The animal protocol used in this study (1039564-2) was approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Nevada, Las Vegas. All experiments and
procedures were conducted in line with the National Institutes of Health’s guidelines in the “Guide for
Care and Use of Laboratory Animals.” Bedding, water, and mouse feed were autoclaved prior to use.
Weaned female C57BL/6 mice were purchased from Charles River (Wilmington, MA) and given 1 week to
acclimate in the animal facility. The following protocols represent animals 5 to 8 weeks old.
Diet specifications. The mouse chow used for each experimental diet (see Table S1 to S4 in the
supplemental material) was purchased from TestDiet and irradiated prior to shipping. The mouse chow
was stored at 4°C before use. Additional diet specifications can be found in Tables S1 to S3.
Treatment groups and experimental timeline. Mice were caged in groups of five, and each mouse
was marked with one of five colors. Feces samples were collected from each individual mouse by stroking
the back of the mouse to induce defecation. Fecal samples were collected beginning at day 0 and for the
duration of the 47-day experiment. All animals were fed a standard laboratory diet until day 3. Animals
were randomly separated into 5 groups (Fig. 1; see also Table S1). Two groups received a standard
laboratory diet (standard laboratory diet and untreated-control standard [CDI]). Three groups received
a high-carbohydrate diet, a high-fat/low-protein diet, or a high-fat/high-protein diet. All groups were fed
their respective diets, and autoclaved water was available ad libitum. On day 13 and for the next 2 days,
all groups except the standard diet (CDI) group were given an antibiotic cocktail (ad libitum in sterile
drinking water, changed daily) containing kanamycin (0.4 mg/ml), gentamicin (0.035 mg/ml), colistin (850
U/ml), metronidazole (0.215 mg/ml), and vancomycin (0.045 mg/ml). After antibiotic treatment, all ani-
mals were given regular drinking water for the remainder of the experiment. On day 16, all groups except
the standard diet (CDI) group were administered a single dose of intraperitoneal clindamycin
(10 mg/kg of body weight) dissolved in autoclaved DI water. Animals in the standard diet (CDI) group
were administered intraperitoneal DI water, the vehicle control for clindamycin. On day 17, animals in all
groups, except those in the standard laboratory diet (CDI) group, were challenged with 108 CFU of C.
difficile R20291 spores by oral gavage. For 30 days following challenge, animals were monitored daily for
signs of CDI. CDI severity scores were assigned following the rubric described in the paragraph below.
Mice were weighed twice daily after challenge inside a biosafety hood. Animals were euthanized 30 days
postinfection, or as soon as CDI symptoms reached a clinical endpoint as described below, so that no
animals experienced unrelieved pain or distress.
Scoring CDI severity. For mice, disease signs were scored using the following rubric (amended from
previously published protocols [21]): pink anogenital area, score of 1; red anogenital area, score of 2;
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lethargy, score of 2; diarrhea/increase in soiled bedding, score of 1; wet tail, score of 2; hunchback
posture, score of 2; 8% to 15% loss of body weight, score of 1; 15% loss of body weight, score of 2.
Animals scoring 2 or less were indistinguishable from noninfected controls and were considered
nondiseased. Animals scoring 3 to 4, with signs consisting of pink anogenital area, lethargy, an increase
of soiled bedding and minor weight loss, were considered to have mild CDI. Animals scoring 5 to 6, with
signs consisting of mild CDI plus red anogenital area and hunchback posture, were considered to have
moderate CDI. Animals scoring 6 were considered to have severe CDI and were immediately eutha-
nized. Dietary changes were not expected to affect the animal negatively. However, if any signs of
distress or disease were observed, procedures were carried out as indicated in the rubric. A two-way
repeated-measures ANOVA was performed to determine the effect of different diets on disease severity
over time. Euthanized mice were also included in the ANOVA calculation and were given a score of 7.
Statistical significance was defined as represented by P values of 0.05.
Illumina sequencing. Fecal samples were collected for microbiome analysis and archived at – 80°C.
DNA was extracted from thawed fecal samples by the use of a QIAamp DNA stool minikit and quantified
using a NanoDrop 1000 spectrophotometer. The V4 region of the 16S rRNA gene was PCR amplified
using modified primers 515F (GTGYCAGCMGCCGCGGTAA) and 806R (GGACTACNVGGGTWTCTAAT), with
the forward primer containing a 12-bp barcode (66). The PCR products were cleaned, quantified, and
pooled at equimolar concentrations. Paired-end sequencing (151 bp by 12 bp by 151 bp) of pooled
amplicons was performed using a MiSeq platform and customized sequencing primers at Argonne
National Laboratory. Over 6.4 million good-quality reads of the V4 region of the 16S rRNA gene from 237
fecal samples were collected throughout the experimental timeline.
Sequence analysis. All sequence-based analysis was performed in QIIME 2 (version 2018.6) (67). Raw
Illumina reads were demultiplexed using sample-specific barcodes; approximately 29,146 reads per sample
were obtained. The sequences were denoised using the dada2-denoise-paired plugin to remove low-quality,
chimeric, and artifactual sequences, and the resulting high-quality sequences were clustered into 2,657
sequence variants (SVs). Taxonomy was assigned to each SV by the use of a sklearn-based taxonomy classifier
that uses a naive Bayes machine learning for classification and a classifier that was trained on the V4 region
of the 16S rRNA gene “Silva 132 99% OTUs full-length sequences” database. SVs assigned to mitochondria,
chloroplast, eukarya, and other unknown domains were excluded from further analysis. A phylogenetic tree
of SVs was created by performing multiple-sequence alignment by the use of MAFFT software followed by
constructing an unrooted tree by the use of FastTree software, and the unrooted tree was then rooted using
the midpoint rooting method. The resultant tree was utilized for subsequent phylogeny-based analysis. Due
to the variations in sequencing depth (2,505 to 76,203 quality-filtered sequences per sample), we performed
alpha and beta diversity analyses at various rarefied sequence depths—5,000, 7,000, 10,000, and 15,000. We
noted no significant differences at each of these rarified depths (data not shown). To maintain a trade-off
between sampling depth and the number of samples, the data shown here were not normalized for
sequencing depth. We also note that a population of C. difficile of very low abundance was observed in the
microbiome of the uninfected control group on day 17, possibly representing airborne spores (see Fig. S6 in
the supplemental material); however, these animals did not display any CDI signs and this population was
quickly cleared.
Analysis of the effects of diet on the gut microbiome. Alpha diversity was estimated by calculating
Shannon, Simpson, and observed SV diversity indices. ANOVA was performed to test if there were
significant differences in alpha diversities in response to diet, antibiotic administration, and CDI. Further,
a Tukey’s honestly significance difference test was performed on the ANOVA output to conduct pairwise
comparisons of alpha diversity indices and to correct for multiple comparisons. Those data included data
that were missing due to mouse death or to an inability to collect fecal samples as a consequence of
disease severity. The SV table, phylogenetic tree, and associated metadata file were then imported in
R (3.5.0) (68) and further analyzed using phyloseq (version 1.25.2) (69) and vegan (version 2.5.2) and
were suitably visualized using ggplot2 (version 3.0.0) and Inkscape. NMDS was performed using
Bray-Curtis dissimilarity, and the relationships of the samples with respect to diet, antibiotic
treatment, and CDI over the course of experiment were displayed using the first two dimensions.
ANOSIM was calculated using a Bray-Curtis dissimilarity matrix. SIMPER (22) was used to identify the
SVs that were contributing to 50% of the observed differences in microbial communities at any time
point during the experiment.
Data availability. Files containing the original unfiltered sequences are available from the NCBI
under BioProject number PRJNA528113. All sequence data and scripts are available from GitHub at
https://github.com/hedlundb/C.diff_Diet_Study.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, EPS file, 0.2 MB.
FIG S2, EPS file, 0.5 MB.
FIG S3, EPS file, 0.4 MB.
FIG S4, EPS file, 0.4 MB.
FIG S5, EPS file, 0.3 MB.
FIG S6, EPS file, 0.2 MB.
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